HAE Insider Trading
HAEMONETICS CORP | Surgical & Medical Instruments & Apparatus
Comprehensive Trading Performance Summary
The investment history of corporate insiders at HAEMONETICS CORP provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Surgical & Medical Instruments & Apparatus sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2011-07-19 22:55 | 2011-07-15 | ALLEN PETER M | Officer - Chief Marketing Officer | OPT+S | $68.35 | 14,000 | $956,969 | 10,100 | 0.0% |
| 2011-07-06 23:51 | 2011-07-05 | CONCANNON BRIAN | Director, Officer - President & CEO | OPT+S | $66.00 | 3,000 | $198,000 | 37,946 | 0.0% |
| 2011-06-07 19:10 | 2011-06-03 | ALLEN PETER M | Officer - Chief Marketing Officer | OPT+S | $66.16 | 8,350 | $552,436 | 10,100 | 0.0% |
| 2011-05-18 21:09 | 2011-05-16 | Gordon Mikael | Officer - President, Haemonetics Europe | SELL | $67.27 | 457 | $30,743 | 5,544 | -7.6% |
| 2011-05-10 23:08 | 2011-05-09 | MERRIMAN RONALD | Director | OPT+S | $67.10 | 10,592 | $710,723 | 5,201 | 0.0% |
| 2011-05-06 22:01 | 2011-05-05 | FOOTE SUSAN BARTLETT | Director | OPT+S | $67.66 | 6,000 | $405,988 | 3,201 | 0.0% |
| 2011-05-04 23:45 | 2011-05-04 | Brancazio Phillip John | Officer - VP, Global Manufacturing | BUY | $46.80 | 67 | $3,136 | 3,052 | +2.2% |
| 2011-05-04 23:46 | 2011-05-04 | White Jonathan | Officer - VP Research and Development | BUY | $46.80 | 455 | $21,294 | 5,040 | +9.9% |
| 2011-05-04 23:46 | 2011-05-04 | Gordon Mikael | Officer - President, Haemonetics Europe | BUY | $46.80 | 257 | $12,028 | 6,001 | +4.5% |
| 2011-05-04 23:46 | 2011-05-04 | LINDOP CHRISTOPHER J | Officer - CFO & Vice President of | BUY | $46.80 | 273 | $12,777 | 11,370 | +2.5% |
| 2011-05-04 23:45 | 2011-05-04 | ALLEN PETER M | Officer - Chief Marketing Officer | BUY | $46.80 | 301 | $14,087 | 10,100 | +3.1% |
| 2011-05-04 23:46 | 2011-05-04 | FORISH JOSEPH J | Officer - VP, Human Resources | BUY | $46.80 | 457 | $21,388 | 6,710 | +7.3% |
| 2011-05-04 23:46 | 2011-05-04 | HANLON SUSAN M | Officer - VP Finance | BUY | $46.80 | 148 | $6,927 | 6,196 | +2.4% |
| 2011-04-01 19:21 | 2011-03-30 | HANLON SUSAN M | Officer - VP Finance | OPT+S | $65.00 | 3,000 | $195,000 | 6,048 | 0.0% |
| 2011-02-14 22:18 | 2011-02-10 | ALLEN PETER M | Officer - Chief Marketing Officer | OPT+S | $59.43 | 1,650 | $98,056 | 9,799 | 0.0% |
| 2011-02-08 21:33 | 2011-02-04 | BEST LAWRENCE C | Director | OPT+S | $61.48 | 32,000 | $1,967,226 | 2,201 | 0.0% |
| 2010-12-28 16:56 | 2010-12-23 | GELBMAN RONALD G | Director | OPT+S | $64.22 | 6,000 | $385,347 | 6,915 | 0.0% |
| 2010-12-15 00:50 | 2010-12-10 | LINDOP CHRISTOPHER J | Officer - CFO & Vice President of | OPT+S | $62.48 | 17,832 | $1,114,220 | 11,097 | 0.0% |
| 2010-12-08 00:17 | 2010-12-03 | LOPEZ ALICIA R | Officer - VP, Corporate Affairs | OPT+S | $60.91 | 96,656 | $5,887,124 | 11,017 | 0.0% |
| 2010-12-07 23:34 | 2010-12-06 | HANLON SUSAN M | Officer - VP Finance | OPT+S | $60.99 | 3,500 | $213,465 | 6,584 | 0.0% |
| 2010-11-09 00:33 | 2010-11-04 | Brancazio Phillip John | Officer - VP, Global Manufacturing | BUY | $46.34 | 74 | $3,429 | 2,985 | +2.5% |
| 2010-11-09 00:57 | 2010-11-04 | White Jonathan | Officer - VP Research and Development | BUY | $46.34 | 4 | $185 | 4,585 | +0.1% |
| 2010-11-09 00:40 | 2010-11-04 | Gordon Mikael | Officer - President, Haemonetics Europe | BUY | $46.34 | 200 | $9,267 | 5,744 | +3.6% |
| 2010-11-09 00:48 | 2010-11-04 | LINDOP CHRISTOPHER J | Officer - CFO & Vice President of | BUY | $46.34 | 297 | $13,762 | 11,237 | +2.7% |
| 2010-11-09 00:28 | 2010-11-04 | ALLEN PETER M | Officer - Chief Marketing Officer | BUY | $46.34 | 328 | $15,198 | 9,799 | +3.5% |
| 2010-11-09 04:37 | 2010-11-04 | MERRIMAN RONALD | Director | OPT+S | $58.11 | 7,000 | $406,762 | 5,201 | 0.0% |
| 2010-11-09 00:54 | 2010-11-04 | RUXIN MICHAEL I | Officer, Other - VP Global Software Strategies | BUY | $46.34 | 215 | $9,962 | 215 | +100.0% |
| 2010-11-09 00:39 | 2010-11-04 | FORISH JOSEPH J | Officer - VP, Human Resources | BUY | $46.34 | 40 | $1,853 | 6,253 | +0.6% |
| 2010-11-09 00:51 | 2010-11-04 | LOPEZ ALICIA R | Officer - VP, Corporate Affairs | BUY | $46.34 | 150 | $6,950 | 11,017 | +1.4% |
| 2010-11-09 00:44 | 2010-11-04 | HANLON SUSAN M | Officer - VP Finance | BUY | $46.34 | 160 | $7,414 | 6,584 | +2.5% |
| 2010-11-09 00:21 | 2010-11-05 | GRANADILLO PEDRO P | Director | SELL | $57.72 | 6,000 | $346,300 | 5,501 | -52.2% |
| 2010-09-15 04:02 | 2010-09-10 | ALLEN PETER M | Officer - Chief Marketing Officer | OPT+S | $54.83 | 1,866 | $102,316 | 5,999 | 0.0% |
| 2010-08-02 23:23 | - | BEST LAWRENCE C | Director | SELL | $53.49 | 100,000 | $5,349,320 | 1,008 | -99.0% |
| 2010-08-02 23:23 | - | BEST LAWRENCE C | Director | BUY | $46.56 | 100,000 | $4,655,860 | 100,000 | +100.0% |
| 2010-05-13 21:40 | 2010-05-11 | GELBMAN RONALD G | Director | SELL | $57.02 | 9,000 | $513,171 | 5,722 | -61.1% |
| 2010-05-05 04:33 | 2010-04-30 | Brancazio Phillip John | Officer - VP, Global Manufacturing | BUY | $45.70 | 68 | $3,108 | 1,548 | +4.6% |
| 2010-05-05 04:37 | 2010-04-30 | White Jonathan | Officer - VP Research and Development | BUY | $45.70 | 460 | $21,024 | 2,808 | +19.6% |
| 2010-05-05 04:35 | 2010-04-30 | LINDOP CHRISTOPHER J | Officer - CFO & Vice President of | BUY | $45.70 | 279 | $12,752 | 8,373 | +3.4% |
| 2010-05-05 04:33 | 2010-04-30 | ALLEN PETER M | Officer - Chief Marketing Officer | BUY | $45.70 | 308 | $14,077 | 7,865 | +4.1% |
| 2010-05-05 04:34 | 2010-04-30 | FORISH JOSEPH J | Officer - VP, Human Resources | BUY | $45.70 | 422 | $19,287 | 4,559 | +10.2% |
| 2010-05-05 04:36 | 2010-04-30 | LOPEZ ALICIA R | Officer - VP, Corporate Affairs | BUY | $45.70 | 318 | $14,534 | 11,009 | +3.0% |
| 2010-05-05 04:35 | 2010-04-30 | HANLON SUSAN M | Officer - VP Finance | BUY | $45.70 | 151 | $6,901 | 5,280 | +2.9% |
| 2010-04-21 01:26 | 2010-04-16 | LOPEZ ALICIA R | Officer - VP, Corporate Affairs | OPT+S | $60.00 | 30,867 | $1,852,020 | 10,691 | 0.0% |
| 2010-04-09 01:44 | 2010-04-06 | CONCANNON BRIAN | Director, Officer - President & CEO | SELL | $56.31 | 165 | $9,291 | 26,747 | -0.6% |
| 2010-03-27 00:31 | 2010-03-25 | NUTTER BRAD | Director, Officer - Chairman of the Board | OPT+S | $57.00 | 26,872 | $1,531,731 | 9,387 | 0.0% |
| 2010-03-25 01:49 | 2010-03-22 | NUTTER BRAD | Director, Officer - Chairman of the Board | OPT+S | $57.00 | 173,128 | $9,868,296 | 9,387 | 0.0% |
| 2010-02-20 00:41 | 2010-02-18 | BEST LAWRENCE C | Director | SELL | $53.42 | 50,000 | $2,670,850 | 1,008 | -98.0% |
| 2010-02-19 01:00 | 2010-02-16 | BEST LAWRENCE C | Director | SELL | $53.57 | 50,000 | $2,678,470 | 51,008 | -49.5% |
| 2010-02-13 01:09 | 2010-02-10 | ALLEN PETER M | Officer - Chief Marketing Officer | OPT+S | $52.56 | 2,200 | $115,632 | 7,557 | 0.0% |
| 2009-11-04 02:32 | 2009-10-30 | White Jonathan | Officer - VP Research and Development | BUY | $44.13 | 480 | $21,183 | 2,348 | +25.7% |
How to Interpret $HAE Trades
Not every insider transaction in HAEMONETICS CORP is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $HAE shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for HAE
Insider activity data for HAEMONETICS CORP is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $HAE, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.